Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

NICE guidance informed by SHTAC report on Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

Published: 1 March 2019
Breast cancer is the most common type of cancer in the UK

The National Institute for Health and Care Excellence (NICE) has issued guidance to the national health service (NHS) on the use of the drug Abemaciclib informed by a report produced by SHTAC.

NICE’s guidance recommends Abemaciclib (Verzenios), with an aromatase inhibitor, is available on the NHS. It is a possible option for adults who have locally advanced or metastatic breast cancer that:

  • is hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)‑negative,
  • and has not been treated with endocrine therapy before.

NICE’s guidance is informed by an evidence review group report prepared by SHTAC, which critically appraised the drug company’s submission to NICE’s Single Technology Appraisal process.

For more information about SHTAC’s previous research into cancer please visit our Research page.



Privacy Settings